AgingResearch.NewsJoin free

E. Merck KG

Company

E. Merck KG develops 4 assets, the furthest approved (dydrogesterone). Mostly small molecule acting on PGR, Mitochondrial biogenesis (PGC-1α) and AMPK signalling.

4
Assets
Furthest stage
Approved
53
Trials
0
Signals

Pipeline

4

  • dydrogesterone

    Activates progesterone receptors to support endometrial preparation and maintenance for pregnancy.

    Approved, Small molecule, PGR, female infertility (Phase 3), infertility (Phase 3)

  • metformin

    Activates AMPK and autophagy to potentially slow cellular drivers of aging.

    Approved, Small molecule, Mitochondrial biogenesis (PGC-1α), AMPK signalling, type 2 diabetes, aging (Phase 3)

  • cholecalciferol

    Vitamin D receptor agonist regulating calcium and phosphate homeostasis

    Phase 3, Small molecule, VDR, osteoporosis, osteoporosis

1 more asset

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

1

In the full profile

  • Evidence behind the mechanisms12
  • Trials101
  • Signals5
  • Similar companies6

Intelligence